Tibotec
{{Short description|Defunct pharmaceutical company (1994–2002)}}
{{Infobox company
| founded = {{start date and age|1994}}
| defunct = {{end date|2002}}
| fate = Acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division
| industry = Pharmaceutical
| founders = {{ubl|Rudi Pauwels|Carine Claeys|Marie-Pierre de Béthune|Kurt Hertogs|Hilde Azijn}}
| website = {{url|tibotec.com}}
}}
Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment.
The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).{{Cite journal |last1=Pauwels |first1=Rudi |last2=Andries |first2=Koen |last3=Desmyter |first3=Jan |last4=Schols |first4=Dominique |last5=Kukla |first5=Michael J. |last6=Breslin |first6=Henry J. |last7=Raeymaeckers |first7=Alfons |last8=Gelder |first8=Jozef Van |last9=Woestenborghs |first9=Robert |last10=Heykants |first10=Jozef |last11=Schellekens |first11=Karel |last12=Janssen |first12=Marcel A. C. |last13=Clercq |first13=Erik De |last14=Janssen |first14=Paul A. J. |year=1990 |title=Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives |journal=Nature |volume=343 |issue=6257 |pages=470–474 |bibcode=1990Natur.343..470P |doi=10.1038/343470a0 |pmid=1689015 |s2cid=4354080}}
History
In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels joined Tibotec. The company was acquired by Johnson & Johnson in April 2002,{{Cite web |date=2002-03-22 |title=Johnson & Johnson to Acquire Tibotec-Virco |url=http://www.investor.jnj.com/ReleaseDetail.cfm?ReleaseID=75177 |url-status=usurped |archive-url=https://web.archive.org/web/20020608123005/http://www.investor.jnj.com/ReleaseDetail.cfm?ReleaseID=75177 |archive-date=2002-06-08 |access-date=2023-05-16 |website=Johnson & Johnson}} and was renamed Janssen Therapeutics in June 2011.{{Cite web |last=Van Houten |first=Pamela |date=2011-06-22 |title=Tibotec Therapeutics Becomes Janssen Therapeutics, Part Of The Janssen Pharmaceutical Companies |url=https://www.jnj.com/media-center/press-releases/tibotec-therapeutics-becomes-janssen-therapeutics-part-of-the-janssen-pharmaceutical-companies |url-status=live |archive-url=https://archive.today/20230517061755/https://www.jnj.com/media-center/press-releases/tibotec-therapeutics-becomes-janssen-therapeutics-part-of-the-janssen-pharmaceutical-companies |archive-date=2023-05-17 |access-date=2023-05-17 |website=Johnson & Johnson |language=en}}
Tibotec provided funding for HIV treatment clinical trials at the Infectious Diseases Institute in Kampala, Uganda.{{Cite web |last=Schmickle |first=Sharon |date=2008-11-13 |title=University of Minnesota doctors battle AIDS in Uganda |url=http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda |url-status=usurped |archive-url=https://web.archive.org/web/20100623113510/http://www.minnpost.com/stories/2008/11/13/4537/university_of_minnesota_doctors_battle_aids_in_uganda |archive-date=2010-06-23 |access-date=2023-05-16 |website=MinnPost}}{{Cite web |title=Clinical Research at the Infectious Diseases Institute |url=https://media.tghn.org/site_finder/sites/documents/Clinical_Research_at_IDI.pdf |url-status=live |archive-url=https://web.archive.org/web/20230517060735/https://media.tghn.org/site_finder/sites/documents/Clinical_Research_at_IDI.pdf |archive-date=2023-05-17 |access-date=2023-05-17 |website=The Global Health Network |publisher=Infectious Diseases Institute}}
Drugs
- Darunavir (TMC114, tradename Prezista), a protease inhibitor
- Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
- Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug{{cite journal | doi = 10.1126/science.1106753| pmid = 15591164| title = A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis| journal = Science| volume = 307| issue = 5707| pages = 223–7| year = 2005| last1 = Andries| first1 = K.| last2 = Verhasselt| first2 = P| last3 = Guillemont| first3 = J| last4 = Göhlmann| first4 = H. W.| last5 = Neefs| first5 = J. M.| last6 = Winkler| first6 = H| last7 = Van Gestel| first7 = J| last8 = Timmerman| first8 = P| last9 = Zhu| first9 = M| last10 = Lee| first10 = E| last11 = Williams| first11 = P| last12 = De Chaffoy| first12 = D| last13 = Huitric| first13 = E| last14 = Hoffner| first14 = S| last15 = Cambau| first15 = E| last16 = Truffot-Pernot| first16 = C| last17 = Lounis| first17 = N| last18 = Jarlier| first18 = V| bibcode = 2005Sci...307..223A| s2cid = 33219841| doi-access = free}}
- Rilpivirine (TMC278, tradename Edurant), an NNRTI
- Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.Zeuzem S, Berg T, Gane E, et al. (2012). TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of the ASPIRE Trial. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18–22, 2012. Abstract 2.
- Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.